Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor
I'm LongbridgeAI, I can summarize articles.
Giant Biogene Holding Co. Ltd. has scheduled its annual general meeting for May 28, 2026, in Xi’an. Shareholders will review the 2025 financial statements and vote on the re-election of three executive directors and the appointment of KPMG as the new auditor. The meeting will also address mandates for share repurchase and issuance, potentially impacting capital management and shareholder returns. The current analyst rating for the stock (HK:2367) is a Buy with a price target of HK$38.70.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments